Immediate effects of use of recombinant bone morphogenetic protein in children having spinal fusion and refusion procedures in United States

Veerasathpurush Allareddy, Veerajalandhar Allareddy, Natalia I Martinez Schlurmann, Sankeerth Rampa, R. P. Nalliah, K. B. Lidsky, A. T. Rotta, Satheesh Elangovan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Study Design. Retrospective study of Nationwide Inpatient Sample (NIS). Objective. The objective of this study is to estimate the prevalence of complications in children who had insertion of recombinant human bone morphogenetic protein (rhBMP) at the time of spinal fusion procedures (SFP) and to examine if the use of rhBMP is associated with an increased risk of complications. Summary of Background Data. Use of rhBMP for SFP has been associated with conflicting safety profile reports in adults. Methods. NIS (years 2004-2010) was used. All patients with age <18 years who had a SFP during hospitalization with or without insertion of rhBMP were selected. Complications were selected based on a literature review of studies examining outcomes of SFP. Association between insertion of rhBMP and occurrence of complications was examined by multivariable logistic regression models. Results. Of the 72,898 children who underwent SFP, 7.1% children had insertion of rhBMP. Overall complication rate was 14.34% (15.2% in rhBMP group and 14.3% in no-rhBMP group). There was no statistically significant difference in the overall complication rate [odds ratio (OR)=1.08, 95% confidence intervals (CI)=0.89-1.30] or among 14 different complications between rhBMP and no-rhBMP groups. Children who had rhBMP were associated with higher odds for ''other infections'' (OR=2.09, 95% CI=1.26-3.48, P=0.004) when compared with their counterparts. Conclusion. Despite the lack of Food and Drug Administration approval, rhBMP was not infrequently used in pediatric SFP. In this large retrospective study using administrative data, the use of rhBMP in children during SFP was not associated with higher risks for majority of assessed complications with the exception of ''other infections''. Future studies must examine the long-term impact of use of rhBMP in children with SFP.

Original languageEnglish (US)
Pages (from-to)1719-1726
Number of pages8
JournalSpine
Volume40
Issue number21
DOIs
StatePublished - Oct 27 2015

Fingerprint

Spinal Fusion
Bone Morphogenetic Proteins
Recombinant Proteins
Inpatients
Retrospective Studies
Logistic Models
Odds Ratio
Confidence Intervals
Drug Approval
United States Food and Drug Administration
Infection

Keywords

  • Bone morphogenetic protein
  • Complications
  • Hospital outcomes
  • Spinal fusions

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Clinical Neurology

Cite this

Allareddy, V., Allareddy, V., Martinez Schlurmann, N. I., Rampa, S., Nalliah, R. P., Lidsky, K. B., ... Elangovan, S. (2015). Immediate effects of use of recombinant bone morphogenetic protein in children having spinal fusion and refusion procedures in United States. Spine, 40(21), 1719-1726. https://doi.org/10.1097/BRS.0000000000001110

Immediate effects of use of recombinant bone morphogenetic protein in children having spinal fusion and refusion procedures in United States. / Allareddy, Veerasathpurush; Allareddy, Veerajalandhar; Martinez Schlurmann, Natalia I; Rampa, Sankeerth; Nalliah, R. P.; Lidsky, K. B.; Rotta, A. T.; Elangovan, Satheesh.

In: Spine, Vol. 40, No. 21, 27.10.2015, p. 1719-1726.

Research output: Contribution to journalArticle

Allareddy, V, Allareddy, V, Martinez Schlurmann, NI, Rampa, S, Nalliah, RP, Lidsky, KB, Rotta, AT & Elangovan, S 2015, 'Immediate effects of use of recombinant bone morphogenetic protein in children having spinal fusion and refusion procedures in United States', Spine, vol. 40, no. 21, pp. 1719-1726. https://doi.org/10.1097/BRS.0000000000001110
Allareddy, Veerasathpurush ; Allareddy, Veerajalandhar ; Martinez Schlurmann, Natalia I ; Rampa, Sankeerth ; Nalliah, R. P. ; Lidsky, K. B. ; Rotta, A. T. ; Elangovan, Satheesh. / Immediate effects of use of recombinant bone morphogenetic protein in children having spinal fusion and refusion procedures in United States. In: Spine. 2015 ; Vol. 40, No. 21. pp. 1719-1726.
@article{697587673e1b4c97bc223be71210c99f,
title = "Immediate effects of use of recombinant bone morphogenetic protein in children having spinal fusion and refusion procedures in United States",
abstract = "Study Design. Retrospective study of Nationwide Inpatient Sample (NIS). Objective. The objective of this study is to estimate the prevalence of complications in children who had insertion of recombinant human bone morphogenetic protein (rhBMP) at the time of spinal fusion procedures (SFP) and to examine if the use of rhBMP is associated with an increased risk of complications. Summary of Background Data. Use of rhBMP for SFP has been associated with conflicting safety profile reports in adults. Methods. NIS (years 2004-2010) was used. All patients with age <18 years who had a SFP during hospitalization with or without insertion of rhBMP were selected. Complications were selected based on a literature review of studies examining outcomes of SFP. Association between insertion of rhBMP and occurrence of complications was examined by multivariable logistic regression models. Results. Of the 72,898 children who underwent SFP, 7.1{\%} children had insertion of rhBMP. Overall complication rate was 14.34{\%} (15.2{\%} in rhBMP group and 14.3{\%} in no-rhBMP group). There was no statistically significant difference in the overall complication rate [odds ratio (OR)=1.08, 95{\%} confidence intervals (CI)=0.89-1.30] or among 14 different complications between rhBMP and no-rhBMP groups. Children who had rhBMP were associated with higher odds for ''other infections'' (OR=2.09, 95{\%} CI=1.26-3.48, P=0.004) when compared with their counterparts. Conclusion. Despite the lack of Food and Drug Administration approval, rhBMP was not infrequently used in pediatric SFP. In this large retrospective study using administrative data, the use of rhBMP in children during SFP was not associated with higher risks for majority of assessed complications with the exception of ''other infections''. Future studies must examine the long-term impact of use of rhBMP in children with SFP.",
keywords = "Bone morphogenetic protein, Complications, Hospital outcomes, Spinal fusions",
author = "Veerasathpurush Allareddy and Veerajalandhar Allareddy and {Martinez Schlurmann}, {Natalia I} and Sankeerth Rampa and Nalliah, {R. P.} and Lidsky, {K. B.} and Rotta, {A. T.} and Satheesh Elangovan",
year = "2015",
month = "10",
day = "27",
doi = "10.1097/BRS.0000000000001110",
language = "English (US)",
volume = "40",
pages = "1719--1726",
journal = "Spine",
issn = "0362-2436",
publisher = "Lippincott Williams and Wilkins",
number = "21",

}

TY - JOUR

T1 - Immediate effects of use of recombinant bone morphogenetic protein in children having spinal fusion and refusion procedures in United States

AU - Allareddy, Veerasathpurush

AU - Allareddy, Veerajalandhar

AU - Martinez Schlurmann, Natalia I

AU - Rampa, Sankeerth

AU - Nalliah, R. P.

AU - Lidsky, K. B.

AU - Rotta, A. T.

AU - Elangovan, Satheesh

PY - 2015/10/27

Y1 - 2015/10/27

N2 - Study Design. Retrospective study of Nationwide Inpatient Sample (NIS). Objective. The objective of this study is to estimate the prevalence of complications in children who had insertion of recombinant human bone morphogenetic protein (rhBMP) at the time of spinal fusion procedures (SFP) and to examine if the use of rhBMP is associated with an increased risk of complications. Summary of Background Data. Use of rhBMP for SFP has been associated with conflicting safety profile reports in adults. Methods. NIS (years 2004-2010) was used. All patients with age <18 years who had a SFP during hospitalization with or without insertion of rhBMP were selected. Complications were selected based on a literature review of studies examining outcomes of SFP. Association between insertion of rhBMP and occurrence of complications was examined by multivariable logistic regression models. Results. Of the 72,898 children who underwent SFP, 7.1% children had insertion of rhBMP. Overall complication rate was 14.34% (15.2% in rhBMP group and 14.3% in no-rhBMP group). There was no statistically significant difference in the overall complication rate [odds ratio (OR)=1.08, 95% confidence intervals (CI)=0.89-1.30] or among 14 different complications between rhBMP and no-rhBMP groups. Children who had rhBMP were associated with higher odds for ''other infections'' (OR=2.09, 95% CI=1.26-3.48, P=0.004) when compared with their counterparts. Conclusion. Despite the lack of Food and Drug Administration approval, rhBMP was not infrequently used in pediatric SFP. In this large retrospective study using administrative data, the use of rhBMP in children during SFP was not associated with higher risks for majority of assessed complications with the exception of ''other infections''. Future studies must examine the long-term impact of use of rhBMP in children with SFP.

AB - Study Design. Retrospective study of Nationwide Inpatient Sample (NIS). Objective. The objective of this study is to estimate the prevalence of complications in children who had insertion of recombinant human bone morphogenetic protein (rhBMP) at the time of spinal fusion procedures (SFP) and to examine if the use of rhBMP is associated with an increased risk of complications. Summary of Background Data. Use of rhBMP for SFP has been associated with conflicting safety profile reports in adults. Methods. NIS (years 2004-2010) was used. All patients with age <18 years who had a SFP during hospitalization with or without insertion of rhBMP were selected. Complications were selected based on a literature review of studies examining outcomes of SFP. Association between insertion of rhBMP and occurrence of complications was examined by multivariable logistic regression models. Results. Of the 72,898 children who underwent SFP, 7.1% children had insertion of rhBMP. Overall complication rate was 14.34% (15.2% in rhBMP group and 14.3% in no-rhBMP group). There was no statistically significant difference in the overall complication rate [odds ratio (OR)=1.08, 95% confidence intervals (CI)=0.89-1.30] or among 14 different complications between rhBMP and no-rhBMP groups. Children who had rhBMP were associated with higher odds for ''other infections'' (OR=2.09, 95% CI=1.26-3.48, P=0.004) when compared with their counterparts. Conclusion. Despite the lack of Food and Drug Administration approval, rhBMP was not infrequently used in pediatric SFP. In this large retrospective study using administrative data, the use of rhBMP in children during SFP was not associated with higher risks for majority of assessed complications with the exception of ''other infections''. Future studies must examine the long-term impact of use of rhBMP in children with SFP.

KW - Bone morphogenetic protein

KW - Complications

KW - Hospital outcomes

KW - Spinal fusions

UR - http://www.scopus.com/inward/record.url?scp=84946058292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946058292&partnerID=8YFLogxK

U2 - 10.1097/BRS.0000000000001110

DO - 10.1097/BRS.0000000000001110

M3 - Article

VL - 40

SP - 1719

EP - 1726

JO - Spine

JF - Spine

SN - 0362-2436

IS - 21

ER -